Features
Managing Treatment Resistance in Neovascular Age-related Macular Degeneration
Novel therapies are on the horizon.
By Asad F. Durrani, MD, Yoshihiro Yonekawa, MD
Glycoimmune Therapy as a Novel Treatment Approach for Geographic Atrophy
A dual-mechanism therapy is in development.
By Sophie J. Bakri, MD, MBA, Jeffrey S. Heier, MD, Arshad M. Khanani, MD, MA, FASRS, et al.
Bispecific Antibodies in Retina Therapies
More targets could mean better efficacy.
By René Rückert, MD, MBA, Gemmy Cheung Chui Ming, FRCOphth, Marion R. Munk, MD, PhD, FEBO
The Current Landscape of Anti-VEGF Biosimilars
New products may reduce the cost of treating retinal diseases.
By Angela S. Li, MD, Sharon Fekrat, MD, FASRS
Web Exclusives
Systemic Medications and Lifestyle Factors in AMD
Studies are under way to determine methods to prevent or delay progression.
By John Moir, BA, Sarthak Aggarwal, BS, Dimitra Skondra, MD, PhD
Departments
UPFRONT: Medicine Evolves
By Peter K. Kaiser, MD
CODING Q&A: Medicare Reimbursement for Discarded Drugs
Understand when to use the JZ or JW modifier on single-dose drug claims.
By Brandy H. Sperry, COMT, COE, CPC, CPMA
UVEITIS CORNER: Uveitis Care Availability in the United States
Recent research explores disparities in care.
By Daniel M. Vu, MD, Ta Chen Peter Chang, MD
CLINICAL TRIAL DOWNLOAD: LIGHTSITE III 24-month Photobiomodulation Results
Noninvasive treatment could slow progression in intermediate AMD.
By Yasha Modi, MD , Matthew W. Russell, MD, Rishi P. Singh, MD, et al.
NEW PRODUCT APPLICATIONS: Laser System Offers Three Advanced Modalities in One Device
Multiple tissue-sparing technology options are available.
By Karen Appold, contributing writer
News
SUBSPECIALTY NEWS: Izervay FDA approval, ReST committee updates on Syfovre, and more.
By Rochelle Nataloni, contributing writer